TABLE 1.

Platelet parameters at visit on days 7 to 9, safety analysis population from ESTABLISH-1 and ESTABLISH-2^a

Patient group	Platelet count (cells/mm3), outcome	Data (no. [%]) for patients taking:		Relative risk (95% CId)
		200 mg tedizolid QD	600 mg linezolid BID
Received ≥1 dose of study drugb	<150,000, <LLN	18 (3.2)	31 (5.6)	0.58 (0.33–1.02)
	<112,500, <75% LLN	8 (1.4)	12 (2.2)	0.66 (0.27–1.61)
	<100,000	6 (1.1)	8 (1.4)	0.75 (0.26–2.14)
	<50,000	1 (0.2)	1 (0.2)	1.00 (0.06–15.86)
	<20,000	0 (0.0)	0 (0.0)	NA
Received ≥1 dose of study drug and had baseline platelet count of >150,000 cells/mm3c	150,000, <LLN	9 (1.9)	9 (1.9)	0.98 (0.39–2.45)
	<112,500, <75% LLN	4 (0.8)	2 (0.4)	1.96 (0.36–10.66)
	<100,000	3 (0.6)	0 (0.0)	NA
	<50,000	1 (0.2)	0 (0.0)	NA
	<20,000	0 (0.0)	0 (0.0)	NA
	≥50% decrease from baseline	3 (0.6)	3 (0.6)	0.98 (0.20–4.84)

^aPatients were randomly assigned to receive once-daily (QD) dosing of tedizolid for 6 days or twice-daily (BID) dosing of linezolid for 10 days.

^bn = 555 tedizolid and 552 linezolid.

^cn = 471 tedizolid and 462 linezolid.

^dCI, confidence interval; NA, not applicable.